AATI’s Advisory Board
Dr Brendan Shaw
Brendan is a former CEO of Medicines Australia. Over the last 10 years, he has managed many key medicines industry issues in Australia (e.g. the Pharmaceutical Benefits Scheme; IP policy, and the increasing internationalisation of Australian medicines). He was also the Board Director for Research Australia, one of the leading not-for-profit organisations commercialising early-stage research.
Prof. David Anderson
David is the Deputy Director at the Burnet Institute. He has been responsible for overall coordination of R&D commercialisation; review and management of IP and new commercial opportunities. In 2013, he established the Burnet spinout Nanjing BioPoint Diagnostic Technology Ltd, as CEO. Nanjing BioPoint raised USD2.5m investment from Chinese PE in 2014, & established ISO13485-certified manufacturing facilities in China.
Russell is the COO of CPIC Allianz Health. He has had significant success commercialising Australian insurance and healthcare start-ups and held roles such as the Director of Operations of the Royal Melbourne Hospital, CEO of Latrobe University Private Hospital etc. and has considerable knowledge across healthcare and medical sectors across Australia, US and throughout Asia.
Shane is the joint Managing Director of Questra Limited, a Queensland based Alternative Assets Funds Management Company. He is an experienced company director with over 18 years in private equity along with 13 years in the corporate world, SME management roles, and running his own business. He possesses strong skills in business strategy, business development, research, process re-engineering and plan execution. Shane holds a MBA, a Graduate Certificate in Applied Finance and Investment, and a Diploma of Company Directors Course from AICD. He is also a Fellow of the Financial Services Institute of Australasia (FinSIA) and a Member of the Australian Institute of Company Directors.